CDK4/6–cyclin D complexes phosphorylate members of the retinoblastoma (Rb) protein family, 6, 12, 25, 26, 27 resulting in the release of the Rb-mediated inhibition of E2F transcription factors.

Cyclin D–CDK4/6 pathway activity is regulated by a number of mitogenic signals, including epidermal growth factors, signaling through the HER2 and estrogen receptors, and the phosphoinositide 3-kinase ...

The cyclin D1-cyclin-dependent kinase 4 (CDK4) complex is a key regulator of the transition through the G₁ phase of the cell cycle. Among the cyclin/CDKs, CDK4 and cyclin D1 are the most frequently ...

Cyclin D and CDK4/6 play a key role in cell-cycle progression by phosphorylating and inactivating the retinoblastoma protein, a tumor suppressor that restrains G1- to S-phase progression. The ...

A new review was published in Genes & Cancer on August 25, 2022, entitled, “CDK4: a master regulator of the cell cycle and its role in cancer.” ...

Tuojie Biotech (Shanghai) Co. Ltd. has prepared oxygen-containing fused tricyclic derivatives acting as CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors. As such, they are reported to be potentially ...

An Allorion Therapeutics (Guangzhou) Co. Ltd. patent discloses aminoheteroaryl CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.

CHICAGO — First-line use of cyclin-dependent kinase 4/6 inhibitors did not confer significant benefit vs. second-line use when added to endocrine therapy for women with hormone receptor-positive ...

Meeting Coverage > ESMO CDK4/6 Inhibition Boosts PFS in Endometrial Cancer — Median PFS more than doubled by adding palbociclib to endocrine therapy by Charles Bankhead, Senior Editor, MedPage ...

Low pre-treatment tumor levels of cyclin A or E associate with long PFS. Credit: npj Breast Cancer (2025). DOI: 10.1038/s41523-025-00767-2 ...

Author: Molina et al Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft models Poster Number: P2-05-29 ...